GlassScriptPhysician profile
Padgett Parker
NPI 1083158802
$1,338.26
in general payments reported to CMS, 2019-2025
15 companies · $816 in 2025
The $816 reported for 2025 was more than what 76% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $35.10 · 2023: $18.90 · 2024: $468 · 2025: $816.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,303.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,303.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $321.68 | 2021-2025 | Evenity, Prolia, Krystexxa |
| Ucb, INC. | $201.50 | 2024-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $166.12 | 2021-2025 | |
| Abbvie INC. | $160.41 | 2024-2025 | |
| Glaxosmithkline, LLC. | $133.91 | 2024-2025 | Benlysta, Shingrix |
| Janssen Biotech, INC. | $108.54 | 2024-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $68.64 | 2024-2025 | Orencia |
| Pfizer INC. | $33.19 | 2025 | |
| Ani Pharmaceuticals, INC. | $28.68 | 2025 | Purified Cortrophin Gel |
| Actelion Pharmaceuticals US, INC. | $25.57 | 2024 | Opsumit |
| Genentech USA, INC. | $20.20 | 2025 | Gazyva |
| Invivyd INC | $20.06 | 2025 | Pemgarda |
| Horizon Therapeutics Plc | $18.90 | 2023 | Krystexxa |
| Kyowa Kirin, INC. | $16.71 | 2024 | Crysvita |
| Sandoz INC. | $14.15 | 2024 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Padgett Parker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.